{
  "trial_id": "NCT03261466",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "randomization",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "homogeneous for number and sex of the subjects",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "supplementation with probiotic containing Bifidobacterium breve B632 and Bifidobacterium breve BR03",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "placebo for a total of 2 months of treatment",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "standard diet according to routine care and practice",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "dietary restriction: 55-60% of carbohydrates, 25-30% lipids and 15% proteins",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "physical activity: all subjects will receive general recommendations about performing physical activity",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "randomization: Participants will be randomly assigned in a 1:1 to probiotic intervention group or placebo group",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "timing: Patients will be evaluated firstly at time of enrollment (V0) and, at the end of the first part of study (Study 1, V1)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "anthropometric measures: height, weight, body mass index (BMI), waist and hip circumferences",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "biochemical evaluations: CBC with formula, serum insulin-like growth factor 1 (IGF1), 25-hydroxy (OH) vitamin D, uric acid, alkaline phosphatase, ACTH, cortisol, TSH, fT4",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "biochemical evaluations: aspartate aminotransferase (AST), alanine aminotransferase (ALT), AST-to-ALT ratio",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Adverse reactions to the product or component of the product",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Genetic obesity (Prader Willi syndrome, Down syndrome)",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Chronic diseases, hepatic or gastroenterological diseases",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Medical treatment for chronic diseases",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient is a 34-year-old woman from Jordan with general and non-specific bones and joints pain. Her past medical and drug history are unremarkable.",
  "_meta": {
    "topic_id": "53",
    "trial_id": "NCT03261466",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}